RxDoctor Payments DataLook up a doctor →

Shirish Gadgeel, MD

Medical Oncology · Detroit, MINPI 1033156534

Payments from drug & device makers

$11,013,551in general payments, 2019–2025

Across 1,570 payments — averaging $7015.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1.7M
  • Merck$1.5M
  • AstraZeneca$1.3M
  • Genentech, Inc.$1.1M
  • Daiichi Sankyo Inc.$1M
  • Pfizer$958K
  • plus $3.4M from 39 others
$54,818in research payments, 2019–2025

Across 56 payments — averaging $978.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$43K
  • Pfizer$8K
  • Amgen$2K
  • Regeneron$1K
  • AbbVie$725

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen46$1,652,420
Merck64$1,519,181
AstraZeneca70$1,316,180
Genentech, Inc.113$1,081,464
Daiichi Sankyo Inc.451$1,048,516
Pfizer93$958,197
AbbVie124$651,340
Astrazeneca UK Limited23$649,750
Mirati Therapeutics, Inc.27$340,134
Janssen Research & Development, LLC39$289,161
Blueprint Medicines Corporation22$264,667
Genmab U.S., Inc.14$212,572
Incyte Corporation167$159,356
Takeda Pharmaceuticals U.S.A., Inc.38$157,655
Regeneron53$113,109
E.r. Squibb & Sons, L.L.C.14$103,753
F. Hoffmann-la Roche AG35$94,224
Exelixis Inc.29$78,583
Helsinn Healthcare SA10$63,972
Eli Lilly4$43,926
Y-mabs Therapeutics, Inc.3$36,150
Otsuka Pharmaceutical Co., Ltd.2$26,207
Bayer16$17,913
Seagen Inc.2$16,500
Johnson & Johnson20$16,108
Iovance Biotherapeutics, Inc.4$15,394
Novartis9$10,878
Gilead10$10,816
Genentech USA, Inc.16$10,042
GSK8$8,320
Boehringer Ingelheim5$7,295
Janssen Scientific Affairs, LLC5$6,065
Janssen Global Services, LLC4$4,920
Eisai Inc.3$4,585
Regeneron Healthcare Solutions, Inc.5$3,869
Roche Products Limited3$3,634
Sanofi2$2,970
Boehringer Ingelheim International GmbH7$2,926
Lilly USA, LLC1$2,800
Hoffmann-la Roche Limited1$2,475
Jazz Pharmaceuticals Inc.1$1,750
Novocure Inc.4$1,500
Bristol Myers Squibb1$1,300
Puma Biotechnology, Inc.1$944
Zap Surgical Systems, Inc.1$33

How this compares

$11,013,551 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan →

Medicare billing

Part B allowed, 2024
$70,800
Medicare patients
131
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Detroit

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →